1h Free Analyst Time
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 45 molecules. Out of which approximately 41 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Drugs In Development, 2022, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 13, 3, 7, 1, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Report covers products from therapy areas Immunology, Hematological Disorders, Central Nervous System, Gastrointestinal, Infectious Disease, Ophthalmology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Musculoskeletal Disorders, Undisclosed, Oncology, Other Diseases and Respiratory which include indications Paroxysmal Nocturnal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Neuromyelitis Optica (Devic's Syndrome), Autoimmune Disorders, Chronic Inflammation, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Lupus Nephritis, Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury, Geographic Atrophy, Guillain-Barre Syndrome, Thrombotic Microangiopathy, Unspecified, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dermatomyositis, IgA Nephropathy (Berger's Disease), Kidney Disease (Nephropathy), Unspecified Immunological Disorders, Uveitis, Acute Lung Injury, Age Related Macular Degeneration, Amyotrophic Lateral Sclerosis, Antiphospholipid Syndrome, Asthma, Atopic Keratoconjunctivitis, Bacterial Sepsis, Bullous Pemphigoid, Cardiovascular Inflammation, Choroidal Neovascularization, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hematuria, Hemorrhagic Shock, Hidradenitis Suppurativa, Intermediate Uveitis, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Lung Disease, Microscopic Polyangiitis (MPA), Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Non-infectious Uveitis, Posterior Uveitis, Primary Progressive Multiple Sclerosis (PPMS), Proteinuria, Pyoderma Gangrenosum, Rheumatoid Arthritis, Sepsis, Septic Shock, Sickle Cell Disease With Vaso-Occlusive Crisis, Squamous Cell Carcinoma, Subarachnoid Hemorrhage, Sudoriferous (Sweat) Gland Disorders, Trauma, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome) and Unspecified Ophthalmological Disorders.
Furthermore, this report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
- The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
- Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
- Featured News & Press Releases
- Sep 27, 2022: Iveric Bio to present top-line results for avacincaptad pegol from phase 3 GATHER2 clinical trial in geographic atrophy at AAO 2022 Annual Meeting
- Sep 26, 2022: EC approves Alexion’s Ultomiris for generalised myasthenia gravis
- Sep 22, 2022: CANbridge Pharmaceuticals data on CAN106 to be presented at two conferences
- Sep 09, 2022: InflaRx to present at upcoming scientific and investor conferences
- Sep 08, 2022: Inflarx announces vilobelimab phase III results in critically ill covid-19 patients published in The Lancet Respiratory Medicine
- Sep 06, 2022: Iveric Bio announces positive topline data from Zimura GATHER2 phase 3 clinical trial in geographic atrophy
- Aug 29, 2022: Alnylam eports positive results from phase 2 study of investigational Cemdisiran for the treatment of IgA Nephropathy
- Aug 26, 2022: Kira Pharmaceuticals to present new preclinical data on lead asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
- Aug 25, 2022: Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis
- Aug 24, 2022: Amgen reports positive data from Phase III trial of biosimilar for PNH
- Aug 10, 2022: Anti-C5 recycling antibody crovalimab obtains priority review in china for the treatment of paroxysmal nocturnal hemoglobinuria
- Aug 03, 2022: ImmunAbs announces US FDA approval for a phase 1 clinical trial
- Aug 01, 2022: Akari Therapeutics narrows pipeline focus
- Jul 28, 2022: Kira Pharmaceuticals receives FDA Orphan Drug Designation for KP104, a bifunctional antibody fusion protein, for the treatment of Paroxysmal Nocturnal Hemoglobinuria
- Jul 28, 2022: Akari Therapeutics announces positive results from recent pre-clinical studies of investigational PASylated nomacopan that support the potential to advance research toward IND/IMPD for clinical trials in geographic atrophy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adienne Pharma & Biotech SA
- Akari Therapeutics Plc
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Amgen Inc
- Aptarion Biotech AG
- Biocad
- CANbridge Life Sciences Ltd
- Chugai Pharmaceutical Co Ltd
- Generium
- ImmunAbs Inc
- InflaRx NV
- ISU ABXIS Co Ltd
- IVERIC bio Inc
- Kira Pharmaceuticals
- Navigen Inc
- Novartis AG
- NovelMed Therapeutics Inc
- Prestige BioPharma Ltd
- Ra Pharmaceuticals Inc
- Rallybio Corp
- Regeneron Pharmaceuticals Inc
- Samsung Bioepis Co Ltd
- Sirnaomics Ltd
- Staidson (Beijing) Biopharmaceuticals Co Ltd
- Staidson BioPharma Inc
- Tasly Biopharmaceuticals Co Ltd
- Vertex Pharmaceuticals Inc
